Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: PD-1/PD-L1 pathway and PD-1 inhibitors have been widely tested in patients with a variety of lymphomas. Nivolumab and pembrolizumab have been approved by the U.S. Food and Drug Administration for treating patients with some types of relapsed or refractory (R/R) lymphomas. The highest response rate has been achieved in patients with CHL, due to a high frequency of genetic alterations of 9p24.1 and high expression of PD-1 ligands. The frequency of alterations of chromosome 9p24.1 and expression of PD-L1/PD-L1 in DLBCL (except some specific subtypes) is low; therefore, it is not recommended to treat unselected DLBCL patients with PD-1 inhibitors. Studies have shown a high frequency of PD-L1 expression in ALCL, especially in anaplastic lymphoma kinase (ALK)+ type. Several cases reports have described a dramatic and durable response to PD-1 blockade in patients with R/R ALCL, suggesting that patients with R/R ALCL may be potential candidates for PD-1 blockade immunotherapy. Understanding the immune biology of lymphoid neoplasms has helped us identify the specific lymphoma types that are vulnerable to PD-1 inhibitors, such as CHL, and specific subtypes of DLBCL. However, our knowledge of many other lymphomas, including ALCL, in this area is still very limited and the future of PD-1 inhibitors in treating those lymphomas remains unclear.
|
Authors | Wei Xie, L Jeffrey Medeiros, Shaoying Li, C Cameron Yin, Joseph D Khoury, Jie Xu |
Journal | Current hematologic malignancy reports
(Curr Hematol Malig Rep)
Vol. 15
Issue 4
Pg. 372-381
(08 2020)
ISSN: 1558-822X [Electronic] United States |
PMID | 32394185
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents, Immunological
- B7-H1 Antigen
- CD274 protein, human
- PDCD1 protein, human
- Programmed Cell Death 1 Receptor
|
Topics |
- Antineoplastic Agents, Immunological
(adverse effects, therapeutic use)
- B7-H1 Antigen
(antagonists & inhibitors, metabolism)
- Hodgkin Disease
(drug therapy, immunology, metabolism, pathology)
- Humans
- Lymphoma, Large B-Cell, Diffuse
(drug therapy, immunology, metabolism, pathology)
- Lymphoma, Large-Cell, Anaplastic
(immunology, metabolism, pathology, therapy)
- Molecular Targeted Therapy
(adverse effects)
- Programmed Cell Death 1 Receptor
(antagonists & inhibitors, metabolism)
- Signal Transduction
- Treatment Outcome
- Tumor Microenvironment
|